The article introduces Inceptive, a biotech startup founded by former Google employee and Transformer inventor Jakob Uszkoreit. The company applies deep learning to drug design, with a core philosophy of enabling the creation of new proteins and drugs through large-scale learning of "biological software languages." The article also discusses the issue of computational resource allocation for LLMs, with Jakob arguing that this is a key factor contributing to the inefficiency of LLMs. Overall, Inceptive represents an intriguing attempt at cross-disciplinary application of LLMs and is worth keeping an eye on for its advancements in the field of drug design.